GlassScriptPhysician profile
Adam Horeish
NPI 1760461206
$3,238.12
in general payments reported to CMS, 2019-2025
30 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $235 · 2021: $235 · 2022: $939 · 2023: $650 · 2024: $206 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Education: $0.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.70 |
| Education | $0.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $404.65 | 2019-2025 | Farxiga, Andexxa |
| Otsuka America Pharmaceutical, INC. | $360.71 | 2019-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $333.52 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $285.59 | 2022-2024 | Tarpeyo |
| Fresenius USA Marketing, INC. | $278.47 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $277.93 | 2021-2022 | |
| Vifor Pharma, INC. | $194.08 | 2020-2022 | |
| Nxstage Medical, INC. | $159.22 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $143.90 | 2025 | Givlaari |
| Horizon Therapeutics Plc | $129.45 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $119.99 | 2023-2025 | Filspari |
| Amgen INC. | $119.98 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $73.81 | 2019 | |
| Akebia Therapeutics INC | $52.74 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.86 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $40.27 | 2019 | |
| Shire North American Group INC | $33.27 | 2019 | |
| Amarin Pharma, INC. | $27.92 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $25.03 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.70 | 2019 | |
| Daiichi Sankyo INC. | $21.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.94 | 2020 | |
| Genzyme Corporation | $19.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.82 | 2022 | |
| Lilly USA, LLC | $16.07 | 2020 | |
| Mannkind Corporation | $15.18 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Horeish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.